Offering patients more: how the West Africa Ebola outbreak can shape innovation in therapeutic research for emerging and epidemic infections
Open Access
- 10 April 2017
- journal article
- review article
- Published by The Royal Society in Philosophical Transactions of the Royal Society B: Biological Sciences
- Vol. 372 (1721) , 20160294
Abstract
Although, after an epidemic of over 28 000 cases, there are still no licensed treatments for Ebola virus disease (EVD), significant progress was made during the West Africa outbreak. The pace of pre-clinical development was exceptional and a number of therapeutic clinical trials were conducted in the face of considerable challenges. Given the on-going risk of emerging infectious disease outbreaks in an era of unprecedented population density, international travel and human impact on the environment it is pertinent to focus on improving the research and development landscape for treatments of emerging and epidemic-prone infections. This is especially the case since there are no licensed therapeutics for some of the diseases considered by the World Health Organization as most likely to cause severe outbreaks—including Middle East respiratory syndrome coronavirus, Marburg virus, Crimean Congo haemorrhagic fever and Nipah virus. EVD, therefore, provides a timely exemplar to discuss the barriers, enablers and incentives needed to find effective treatments in advance of health emergencies caused by emerging infectious diseases. This article is part of the themed issue ‘The 2013–2016 West African Ebola epidemic: data, decision-making and disease control’.Keywords
Funding Information
- The Rhodes Trust (n/a)
- EU FP7 (PREPARE (602525))
- Wellcome Trust of Great Britain ((grant number 106491/ Z/14/Z))
This publication has 30 references indexed in Scilit:
- BCX4430, a Novel Nucleoside Analog, Effectively Treats Yellow Fever in a Hamster ModelAntimicrobial Agents and Chemotherapy, 2014
- Simplified Severe Sepsis ProtocolCritical Care Medicine, 2014
- Reversion of advanced Ebola virus disease in nonhuman primates with ZMappNature, 2014
- Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal modelAntiviral Research, 2014
- Modeling the Impact of Interventions on an Epidemic of Ebola in Sierra Leone and LiberiaPLoS Currents, 2014
- Estimating age‐specific cumulative incidence for the 2009 influenza pandemic: a meta‐analysis of A(H1N1)pdm09 serological studies from 19 countriesInfluenza and Other Respiratory Viruses, 2013
- The FEAST trial of fluid bolus in African children with severe infectionThe Lancet, 2012
- The 2009 A (H1N1) influenza virus pandemic: A reviewVaccine, 2010
- Peptide Bβ15-42 Preserves Endothelial Barrier Function in ShockPLOS ONE, 2009
- Treatment of Ebola Hemorrhagic Fever with Blood Transfusions from Convalescent PatientsThe Journal of Infectious Diseases, 1999